Meeting
2023 ASCO Annual Meeting
Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study.
Authors
Chloe Lim
University of Calgary, Calgary, AB, Canada
Chloe Lim , Sunita Ghosh , Hali Morrison , Daniel E. Meyers , Igor Stukalin , Samantha Dolter , Heidi A.I. Grosjean , Marc Kerba , Desiree Hao , Aliyah Pabani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8561)
DOI
10.1200/JCO.2023.41.16_suppl.8561
Abstract #
8561
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
PEMBROBLAD: Real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants.
First Author: Karim Amrane Sr.
Poster
2023 ASCO Annual Meeting
Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.
First Author: Heather Derry-Vick
Poster
2022 ASCO Annual Meeting
Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer.
First Author: Wakako Daido
Poster
2022 ASCO Annual Meeting
Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.
First Author: Elio Adib